Genome Editing Market Size, Share & Trends Report

Genome Editing Market Size, Share & Trends Analysis Report By Technology (CRISPR/Cas9, ZFN), By Delivery Method (Ex-vivo, In-vivo), By Application, By Mode, By End-use, By Region, And Segment Forecasts, 2024 - 2030

  • Report ID: GVR-1-68038-399-7
  • Number of Report Pages: 120
  • Format: PDF, Horizon Databook
  • Historical Range: 2018 - 2023
  • Forecast Period: 2024 - 2030 
  • Industry: Healthcare

Research Methodology

A three-pronged approach was followed for deducing the genome editing market estimates and forecasts. The process has three steps: information procurement, analysis, and validation. The whole process is cyclical, and steps repeat until the estimates are validated. The three steps are explained in detail below:

Information procurement: Information procurement is one of the most extensive and important stages in our research process, and quality data is critical for accurate analysis. We followed a multi-channel data collection process for genome editing market to gather the most reliable and current information possible.

  • We buy access to paid databases such as Hoover’s and Factiva for company financials, industry information, white papers, industry journals, SME journals, and more.
  • We tap into Grand View’s proprietary database of data points and insights from active and archived monitoring and reporting.
  • We conduct primary research with industry experts through questionnaires and one-on-one phone interviews.
  • We pull from reliable secondary sources such as white papers and government statistics, published by organizations like WHO, NGOs, World Bank, etc., Key Opinion Leaders (KoL) publications, company filings, investor documents, and more.
  • We purchase and review investor analyst reports, broker reports, academic commentary, government quotes, and wealth management publications for insightful third-party perspectives.

Analysis: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilized different methods of genome editing market data depending on the type of information we’re trying to uncover in our research.

  • Market Research Efforts: Bottom-up Approach for estimating and forecasting demand size and opportunity, top-down Approach for new product forecasting and penetration, and combined approach of both Bottom-up and Top-down for full coverage analysis.

  • Value-Chain-Based Sizing & Forecasting: Supply-side estimates for understanding potential revenue through competitive benchmarking, forecasting, and penetration modeling.

  • Demand-side estimates for identifying parent and ancillary markets, segment modeling, and heuristic forecasting.

  • Qualitative Functional Deployment (QFD) Modelling for market share assessment.

Market formulation and validation: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilize different methods of data analysis depending on the type of information we’re trying to uncover in our research.

  • Market Formulation: This step involves the finalization of market numbers. This step on an internal level is designed to manage outputs from the Data Analysis step.

  • Data Normalization: The final market estimates and forecasts are then aligned and sent to industry experts, in-panel quality control managers for validation.

  • This step also entails the finalization of the report scope and data representation pattern.

  • Validation: The process entails multiple levels of validation. All these steps run in parallel, and the study is forwarded for publishing only if all three levels render validated results.

Genome Editing Market Categorization:

The genome editing market was categorized into four segments, namely technology (Meganucleases, (CRISPR)/Cas9, TALENs/MegaTALs, ZFN), delivery method (Ex-vivo, In-vivo), mode (Contract, In-house), end-use (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Contract Research Organizations), application (Genetic Engineering, Clinical Applications), and regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa).

Segment Market Methodology:

The genome editing market was segmented into technology, delivery method, mode, end-use, and regions. The demand at a segment level was deduced using a funnel method. Concepts like the TAM, SAM, SOM, etc., were put into practice to understand the demand. We at GVR deploy three methods to deduce market estimates and determine forecasts. These methods are explained below:

Market research approaches: Bottom-up

  • Demand estimation of each product across countries/regions summed up to from the total market.

  • Variable analysis for demand forecast.

  • Demand estimation via analyzing paid database, and company financials either via annual reports or paid database.

  • Primary interviews for data revalidation and insight collection.

Market research approaches: Top-down

  • Used extensively for new product forecasting or analyzing penetration levels.

  • Tool used invoice product flow and penetration models Use of regression multi-variant analysis for forecasting Involves extensive use of paid and public databases.

  • Primary interviews and vendor-based primary research for variable impact analysis.

Market research approaches: Combined

  • This is the most common method. We apply concepts from both the top-down and bottom-up approaches to arrive at a viable conclusion.

Regional Market Methodology:

The genome editing market was analyzed at a regional level. The globe was divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, keeping in focus variables like consumption patterns, export-import regulations, consumer expectations, etc. These regions were further divided into twenty-three countries, namely, the U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia; UAE; Kuwait

All three above-mentioned market research methodologies were applied to arrive at regional-level conclusions. The regions were then summed up to form the global market.

Genome editing market companies & financials:

The genome editing market was analyzed via companies operating in the sector. Analyzing these companies and cross-referencing them to the demand equation helped us validate our assumptions and conclusions. Key market players analyzed include:

  • Merck KGaA is a German multinational company that offers the provision of healthcare solutions and materials. It operates in three sectors: healthcare, life sciences, and performance materials. It has worldwide operations in North America, Europe, Asia, Oceania, Latin America, and Africa. This company offers products for biopharmaceuticals, consumer health, allergopharma, biosimilars, and life science companies. In November 2015, Merck announced the acquisition of Sigma Aldrich Co. LLC, and it began operating as a subsidiary of Merck KGaA.

  • Cibus, headquartered in California, the U.S., is a privately held company that offers plant and microbial platforms. It provides gene editing and non-transgenic breeding technologies. This company launched “SU Canola” as its first commercial crop. SU Canola is a non-transgenic herbicide that can tolerate sulfonylurea and has received regulatory approval in Canada. It has three centers in the U.S. and Europe. The company’s genetically modified product portfolio includes SU Canola, Flax, Rice, and Potato. In January 2014, Cibus acquired Nucelis and now Nucelis operates as an independent unit of Cibus.           

  • Recombinetics, Inc. is a privately held company that is involved in the development of proprietary gene editing and gene repair technology. The company uses its gene editing technology to improve the agriculture industry. It also works on improving the natural characteristics of livestock for advanced food production and safety. This company is also engaged in the creation of animal models for the investigation of human diseases. It uses two gene editing technologies: Transcription Activator-Like Effector Nucleases (TALENs) and Clustered, Regularly Interspaced, Short Palindromic Repeats (CRISPR), to deliver solutions for livestock producers and medical researchers. The company’s subsidiary Acceligen offers precision breeding technology to the livestock, meat, and milk, production industries. The company is involved in research on diseases through two subsidiaries: Surrogen and Regenevida. It holds exclusive license rights for TALENs.

  • Sangamo Therapeutics is a biopharmaceutical company that develops and offers therapeutics for infectious diseases. Its therapeutic products are developed using Zinc Finger DNA-binding Protein (ZFP) genome editing and Adeno-Associated Virus (AAV) gene therapy platforms. This company has collaborated with Biogen, Inc. and Shire International GmbH to develop therapeutics for hemoglobinopathies and Huntington’s disease respectively. The company is involved in developing products for HIV/AIDS, Huntington’s disease, hemophilia, hemoglobinopathies, and lysosomal storage disorders. It has granted an exclusive license to Sigma-Aldrich Corporation and Dow AgroSciences, LLC for using its ZFP platform for the development of human therapeutics. It has also granted nonexclusive licenses to Genentech Inc.; F. Hoffmann-La Roche Ltd; and Open Monoclonal Technology, Inc. to use its ZFP platform.     

  • Editas Medicine, a public company, is focused on developing genomic medicines. It is involved in the development of transformative medicines for chronic diseases. This company uses the CRISPR gene editing technology to serve different areas of research, including eye diseases, muscle diseases, blood diseases, lung diseases, liver diseases, and cancer. It has developed a CRISPR/Cas9 technology-based proprietary genome editing platform. The company collaborated with Juno Therapeutics to accelerate the development of the next generation of engineered T-cell therapies for cancer immunotherapy.     

  • Precision BioSciences is a privately owned biotechnology company that is involved in the manufacturing and marketing of therapeutics and services based on genomic molecular biology. It provides a platform for cancer immunotherapy, gene therapy, and the food industry. It offers gene editing technology that enables the tackling of genetic diseases and cancer and allows the enhancement of productive food sources.     

  • CRISPR Therapeutics is a privately held company that manufactures and commercializes transformative gene-based medicine for the treatment of chronic diseases. The company develops transformative gene-based therapeutics using its CRISPR/Cas9 gene-editing platform. It has established partnerships with Vertex Pharmaceuticals and Bayer AG to accelerate the development of CRISPR-based medicines. The company operates in London and Massachusetts.

  • Intellia Therapeutics, Inc., based in Massachusetts, U.S., is a gene editing company that offers curative gene editing using CRISPR/Cas9 technology. The company is involved in broadening the therapeutic applications of the CRISPR/Cas9 system. It has received a license for utilizing CRISPR/Cas9 systems for genome editing and advancement of these systems & their components for therapeutic use in humans. The company has also received a license for cell expansion technology to develop stem cell-based therapies and lipid nanoparticles for delivering biomolecules into cells.

  • Caribou Biosciences, Inc. is a privately held company that focuses on genome engineering. The company delivers CRISPR-Cas9 technology-based solutions for cellular engineering. It provides a CRISPR-Cas gene editing technology platform that allows gene targeting for life sciences applications such as industrial biotechnology, agricultural biotechnology, basic & applied biological research, and therapeutic development. It has formed collaborations with DuPont, Genus, Intellia Therapeutics, and Novartis Institutes for Biomedical Research.

  • Cellectis is a biopharmaceutical company headquartered in Paris, France that develops and commercializes gene-edited engineered CAR T-cells. This company aims to develop engineered T-cell-based cancer therapies. It capitalizes on Pulse Agile electroporation technology for the development of immunotherapies. The company owns a registered TALEN trademark. It offers a platform for immuno-oncology, therapeutics, and gene editing. In May 2015, Cellectis Plant Sciences, Inc. (a subsidiary of Cellectis), a Minnesota-based company, changed its name to Calyxt, Inc.

Value chain-based sizing & forecasting

Supply Side Estimates

  • Company revenue estimation via referring to annual reports, investor presentations, and Hoover’s.

  • Segment revenue determination via variable analysis and penetration modeling.

  • Competitive benchmarking to identify market leaders and their collective revenue shares.

  • Forecasting via analyzing commercialization rates, pipelines, market initiatives, distribution networks, etc.

Demand side estimates

  • Identifying parent markets and ancillary markets

  • Segment penetration analysis to obtain pertinent

  • revenue/volume

  • Heuristic forecasting with the help of subject matter experts

  • Forecasting via variable analysis

Genome Editing Market Report Objectives:

  • Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the countries.

  • Understanding trends & variables in the individual countries & their impact on growth and using analytical tools to provide high-level insights into the market dynamics and the associated growth pattern.

  • Understanding market estimates and forecasts (with the base year as 2022, historic information from 2018 - 2021, and forecast from 2023 to 2030). Regional estimates & forecasts for each category are available and are summed up to form the global market estimates.

Genome Editing Market Report Assumptions:

  • The report provides market value for the base year 2022 and a yearly forecast till 2030 in terms of revenue/volume or both. The market for each of the segment outlooks has been provided on region & country basis for the above-mentioned forecast period.

  • The key industry dynamics, major technological trends, and application markets are evaluated to understand their impact on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis.

  • We have used the bottom-up approach for market sizing, analyzing key regional markets, dynamics, & trends for various products and end-users. The total market has been estimated by integrating the country markets.

  • All market estimates and forecasts have been validated through primary interviews with the key industry participants.

  • Inflation has not been accounted for to estimate and forecast the market.

  • Numbers may not add up due to rounding off.

  • Europe consists of EU-8, Central & Eastern Europe, along with the Commonwealth of Independent States (CIS).

  • Asia Pacific includes South Asia, East Asia, Southeast Asia, and Oceania (Australia & New Zealand).

  • Latin America includes Central American countries and the South American continent

  • Middle East includes Western Asia (as assigned by the UN Statistics Division) and the African continent.

Primary Research

GVR strives to procure the latest and unique information for reports directly from industry experts, which gives it a competitive edge. Quality is of utmost importance to us, therefore every year we focus on increasing our experts’ panel. Primary interviews are one of the critical steps in identifying recent market trends and scenarios. This process enables us to justify and validate our market estimates and forecasts to our clients. With more than 8,000 reports in our database, we have connected with some key opinion leaders across various domains, including healthcare, technology, consumer goods, and the chemical sector. Our process starts with identifying the right platform for a particular type of report, i.e., emails, LinkedIn, seminars, or telephonic conversation, as every report is unique and requires a differentiated approach.

We send out questionnaires to different experts from various regions/ countries, which is dependent on the following factors:

What questions do you have? Get quick response from our industry experts. Request a Free Consultation



This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.



We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member


ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon